search
Back to results

Study of Predictor of Mood Relapse in Bipolar Disorders (RechuteBP)

Primary Purpose

Bipolar Disorder, Euthymic State

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Experimental follow up
Genetic sample
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Bipolar Disorder focused on measuring Bipolar disorder, relapse risk factors, prospective follow up

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Bipolar disorder I or II
  • French language
  • Aging between 18 years and 55 years
  • Young Mania Rating Scale (YMRS) < 12
  • Montgomery Asberg Depression Rating Scale (MDRS) < 10

Exclusion Criteria:

  • Rapid cycling
  • Undefined number of major relapses
  • Drug and alcohol abuse within 6 months
  • Electroconvulsive therapy (ECT) within 12 months
  • Epilepsy, traumatism cranial or other neurological diseases
  • Daltonism or visual trouble

Sites / Locations

  • Fernand Widal Hospital

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

experimental arm

Arm Description

Experimental follow up : Neuropsychological assessment at 6 month and genetic samples

Outcomes

Primary Outcome Measures

Combined outcome based on AIM and ALS's score assessed at baseline in euthymic bipolar patients associated with relapse in patients during a 2 years follow-up period.

Secondary Outcome Measures

Global neuropsychological performance based on combined score of all neuropsychological scales (detail below) at T0, measured in euthymic patients predict relapse during a 2 years follow-up period.
Neuropsychological scales : intellectual functioning, episodic verbal memory, processing speed, attention, working verbal memory, working visual memory, executive function
Global neuropsychological deficits based on combined score of all neuropsychological scales (detail below) observed in euthymic bipolar patients that contribute to functional impairment worsen with time
Neuropsychological scales : intellectual functioning, episodic verbal memory, processing speed, attention, working verbal memory, working visual memory, executive function

Full Information

First Posted
August 13, 2015
Last Updated
June 19, 2017
Sponsor
Assistance Publique - Hôpitaux de Paris
search

1. Study Identification

Unique Protocol Identification Number
NCT02572674
Brief Title
Study of Predictor of Mood Relapse in Bipolar Disorders
Acronym
RechuteBP
Official Title
Study of Predictor of Mood Relapse in Bipolar Disorders : Prospective, Clinical, Neuropsychological, Biological and Genetic Study
Study Type
Interventional

2. Study Status

Record Verification Date
June 2017
Overall Recruitment Status
Unknown status
Study Start Date
May 2010 (undefined)
Primary Completion Date
August 2016 (Actual)
Study Completion Date
December 2017 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Study in 400 patients with bipolar disorder I or II, of relapse risk factors. The principal objective of this research is to test the predictive value of core vulnerability dimensions such as affective instability and emotional reactivity, measured by validated questionnaires (AIM and ALS) on recurrence of affective major episode (depressed, hypomanic or manic) during a 24 months prospective follow-up. In addition, several arguments suggest that inter-individual variability in the risk of relapse is influenced by genetic factors. In particular, the implication of such factors have been demonstrated in rapid cycling or antidepressants induced mania. However, this has never been tested in cohorts followed prospectively. Finally, the existence of neuropsychological deficits in bipolar disorder is well documented and their role in the risk of relapse is suspected. Yet the nature of these deficits, their origin and evolutionary course remain poorly investigated. In summary, the secondary objectives of this research are the study of the influence of these other clinical, neuropsychological and genetic factors on the risk of relapse. • Scientific rationale The dimensions of affective instability and emotional reactivity, are considered core psychological and temperamental vulnerability dimensions to bipolar disorder. Differences in levels of instability and reactivity may account for the inter-individual variability observed in bipolar disorder in terms of risk of relapse. These dimensions are measured using validated questionnaires (Affective Instability Measure (AIM) and Affective Lability Scale (ALS)). Relapsing is defined as the occurrence of a depressive episode, hypomanic, manic or mixed episode (DSMIV criteria). Other factors that may influence the risk of relapse have been suggested in the literature but have not been formally tested in prospective studies: cognitive deficits: the existence of neuropsychological deficits in bipolar disorder are well documented and their role in the risk of relapse is suspected. Yet the nature of these deficits, their origin and their course remain poorly investigated. Indeed, some appear to be related to the neurotoxicity of the episodes themselves, the other being related to the vulnerability to bipolar disorder The involvement of genetic vulnerability factors in bipolar disorder is widely demonstrated. Several arguments suggest the implication of genetic factors in the risk of relapse. This is the case for some outcome patterns such as rapid cycling or antidepressants induced mania. Again, this has never been tested in cohorts followed prospectively. The role of certain inflammatory and infectious factors in the etiology of bipolar disorder has been suggested but it is clear whether these biomarkers are "state" or "traits". Thus, the role of neurotoxic inflammatory or infectious factors in relapse mood has never been tested in a prospective follow up studies. Main objective of the project To determine if the scores of AIM and ALS, assessed at baseline in euthymic bipolar patients is associated with relapse in patients during a 2 years follow-up period. Secondary objectives of the project Determine if the neuropsychological performance at T0, measured in euthymic patients predict relapse during a 2 years follow-up period. Determine whether the neuropsychological deficits observed in euthymic bipolar patients that contribute to functional impairment worsen with time. DNA collection to test the involvement of candidate genes Serum collection to study the biological and infectious biomarkers • Methodology Prospective follow up studies. Multicenter.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bipolar Disorder, Euthymic State
Keywords
Bipolar disorder, relapse risk factors, prospective follow up

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
274 (Actual)

8. Arms, Groups, and Interventions

Arm Title
experimental arm
Arm Type
Other
Arm Description
Experimental follow up : Neuropsychological assessment at 6 month and genetic samples
Intervention Type
Other
Intervention Name(s)
Experimental follow up
Intervention Description
Neuropsychological assessment (intellectual functioning, episodic verbal memory, processing speed, attention, working verbal memory, working visual memory, executive function)
Intervention Type
Genetic
Intervention Name(s)
Genetic sample
Intervention Description
Blood samples
Primary Outcome Measure Information:
Title
Combined outcome based on AIM and ALS's score assessed at baseline in euthymic bipolar patients associated with relapse in patients during a 2 years follow-up period.
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Global neuropsychological performance based on combined score of all neuropsychological scales (detail below) at T0, measured in euthymic patients predict relapse during a 2 years follow-up period.
Description
Neuropsychological scales : intellectual functioning, episodic verbal memory, processing speed, attention, working verbal memory, working visual memory, executive function
Time Frame
24 months
Title
Global neuropsychological deficits based on combined score of all neuropsychological scales (detail below) observed in euthymic bipolar patients that contribute to functional impairment worsen with time
Description
Neuropsychological scales : intellectual functioning, episodic verbal memory, processing speed, attention, working verbal memory, working visual memory, executive function
Time Frame
24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Bipolar disorder I or II French language Aging between 18 years and 55 years Young Mania Rating Scale (YMRS) < 12 Montgomery Asberg Depression Rating Scale (MDRS) < 10 Exclusion Criteria: Rapid cycling Undefined number of major relapses Drug and alcohol abuse within 6 months Electroconvulsive therapy (ECT) within 12 months Epilepsy, traumatism cranial or other neurological diseases Daltonism or visual trouble
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Frank BELLIVIVIER, MD PhD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fernand Widal Hospital
City
Paris
ZIP/Postal Code
75010
Country
France

12. IPD Sharing Statement

Learn more about this trial

Study of Predictor of Mood Relapse in Bipolar Disorders

We'll reach out to this number within 24 hrs